论文部分内容阅读
目的探讨脑胶质母细胞瘤中O-6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)基因启动子甲基化状态和MGMT蛋白表达水平与临床预后的相关性。方法收集119例人脑胶质母细胞瘤石蜡包埋样本,提取基因组DNA并进行亚硫酸氢盐修饰,用MethyLight法检测MGMT基因启动子甲基化状态,用免疫组织化学染色法检测MGMT蛋白表达水平,对MGMT基因启动子甲基化状态和MGMT表达水平与患者预后行相关性分析。结果在119例胶质母细胞瘤样本中,有42例检测到MGMT基因启动子甲基化,甲基化发生率为35.3%(42/119例),MGMT基因启动子甲基化与无进展生存期(P=0.011)及总体生存期(P=0.036)延长相关。MGMT蛋白表达水平和临床预后无相关性(P>0.05),与MGMT基因启动子甲基化状态之间也无相关性(P>0.05)。结论 MGMT基因启动子甲基化与胶质母细胞瘤患者预后呈正相关,由免疫组化法测得的MGMT蛋白表达水平和预后及基因启动子甲基化之间无关联性,MGMT基因启动子甲基化状态可以作为评判预后的生物学指标之一。
Objective To investigate the relationship between the methylation status of MGMT promoter and MGMT protein expression in glioma with clinical prognosis. Methods A total of 119 samples of human glioblastoma tumor paraffin-embedded samples were collected, genomic DNA was extracted and subjected to bisulfite modification. The methylation status of MGMT gene promoter was detected by MethyLight method. The expression of MGMT protein was detected by immunohistochemical staining Level of MGMT gene promoter methylation status and MGMT expression levels in patients with prognosis of the line analysis. Results Among the 119 glioblastoma samples, 42 MGMT gene promoter methylation was detected in 42 cases, the methylation rate was 35.3% (42/119 cases), MGMT gene promoter methylation and no progress Survival (P = 0.011) and overall survival (P = 0.036). There was no correlation between MGMT protein expression and clinical prognosis (P> 0.05), and no correlation with MGMT promoter methylation status (P> 0.05). Conclusion The promoter methylation of MGMT gene is positively correlated with the prognosis of patients with glioblastoma. The expression of MGMT protein by immunohistochemistry has no correlation with prognosis and gene promoter methylation. The promoter of MGMT gene Methylation status can be used as one of the biological indicators to judge the prognosis.